RHHBY Roche Holding Ltd Sponsored ADRs

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, obesity, ophthalmology, osteoporosis, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, and women's health, as well oncology. In addition, it provides supplies a array of instruments and reagents, and test kits for use in the diverse research market. The company was founded in 1896 and is headquartered in Basel, Switzerland. This is an ADR of a company whose stock trades outside of the U.S. as the symbol VX:ROG.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$41.93    OTCQX
As of 04/09/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  Switzerland
Country of incorporation:  Switzerland
IPO date:  07/11/2001
Outstanding shares:  5,620,501,600
Average volume:  1,716,086
Market cap:   $235,667,632,088
Current dividend yield:  23.65%
CUSIP:    771195104
ISIN:        US7711951043
Sedol:      
Valuation   (See tab for details)
PE ratio:   18.77
PB ratio:   7.09
PS ratio:   2.96
Return on equity:   42.07%
Net income %:   20.79%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy